# Azacitidine and Recombinant Interferon Alfa-2b in Treating Patients With Stage III or Stage IV Melanoma or Stage IV Kidney Cancer That Cannot Be Removed By Surgery

> **NCT00217542** · PHASE1 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 42 (actual)

## Conditions studied

- Recurrent Melanoma
- Recurrent Renal Cell Cancer
- Stage III Melanoma
- Stage IV Melanoma
- Stage IV Renal Cell Cancer

## Interventions

- **BIOLOGICAL:** recombinant interferon alfa-2b
- **DRUG:** amifostine/azacitidine

## Key facts

- **NCT ID:** NCT00217542
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-07
- **Primary completion:** 2008-07
- **Final completion:** —
- **Target enrollment:** 42 (ACTUAL)
- **Last updated:** 2013-05-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00217542

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00217542, "Azacitidine and Recombinant Interferon Alfa-2b in Treating Patients With Stage III or Stage IV Melanoma or Stage IV Kidney Cancer That Cannot Be Removed By Surgery". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00217542. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*